This product is a highly selective β-receptor blocker that dilates blood vessels and lowers blood pressure by blocking β1 receptors. This product highly selectively binds to β1 receptors on the myocardial cell membrane, and its affinity is 20 to 30 times stronger than that of bronchial and vascular smooth muscle β2 receptors. It can reduce heart rate and cardiac output during rest and exercise, reduce systolic blood pressure during exercise, and inhibit tachycardia induced by isoproterenol. For healthy people, this product cannot reverse the vasodilatory effect of isoproterenol mediated by β2 receptors. This product has intrinsic sympathomimetic activity, does not increase respiratory resistance, dilates peripheral blood vessels, and improves blood circulation. This product has no membrane stabilizing effect, nor does it inhibit myocardial contractility. It is less likely to cause sinus bradycardia than other β-receptor blockers without endogenous sympathomimetic activity. This product can pass through the placental barrier.

Antifungal drugs, which are active against dermatophytes, molds, and yeasts (such as Candida albicans), and are also effective against some gram-positive bacteria

Glucocorticoids, which have anti-inflammatory, antipruritic and anti-allergic effects

Lactic acid is an α-hydroxy acid that exerts its therapeutic effect by inhibiting ion bond-forming enzymes, weakening the mutual attraction between the positively and negatively charged groups of stratum corneum cells and keratinocytes, thereby reducing the cohesion between stratum corneum cells.

Urea dissolves keratin and increases the hydration of the protein, thereby softening and dissolving the cuticle.

This product is a semi-synthetic 14-membered macrolide antibiotic. The antibacterial spectrum and antibacterial effect are basically similar to those of erythromycin. It is slightly less effective than erythromycin against Gram-positive bacteria, and stronger than erythromycin against Legionella pneumophila. The antimicrobial effect against Chlamydia pneumoniae, Mycoplasma pneumoniae, and Ureaplasma urealyticum is similar to or slightly stronger than that of erythromycin. This product can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor ("P" position), blocking the transfer RNA (t-RNA) binding to the "P" position, and also blocking the transfer of the polypeptide chain from the acceptor position ("A" position) to the "P" position, thereby inhibiting bacterial protein synthesis.

This product is a semi-synthetic 14-membered macrolide antibiotic. The antibacterial spectrum and antibacterial effect are basically similar to those of erythromycin. It is slightly less effective than erythromycin against Gram-positive bacteria, and stronger than erythromycin against Legionella pneumophila. The antimicrobial effect against Chlamydia pneumoniae, Mycoplasma pneumoniae, and Ureaplasma urealyticum is similar to or slightly stronger than that of erythromycin. This product can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor ("P" position), blocking the transfer RNA (t-RNA) binding to the "P" position, and also blocking the transfer of the polypeptide chain from the acceptor position ("A" position) to the "P" position, thereby inhibiting bacterial protein synthesis.